SNY vs SYRE
Sanofi vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
SNY
Sanofi
62
Insufficient Data
VS
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
| Metric | SNY | SYRE |
|---|
| AI Score |
62
|
67
|
| Price |
$43.56
|
$102.72
|
| P/E Ratio |
23.06×
|
-52.69×
|
| ROE |
10.9%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.8%
|
0.0%
|
| Debt / Equity |
0.34×
|
0.00×
|
| Dividend Yield |
5.5%
|
0.0%
|
| RSI (14) |
53.1
|
53.3
|
| Beta |
0.278
|
3.026
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for SNY versus SYRE.
SYRE leads by 5 points.
SYRE scores 67/100 (Insufficient Data) versus SNY at 62/100 (Insufficient Data).
SNY Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical